Ivan Burkov

Ivan Burkov is the current Principal at INKEF Capital. Prior to this, they were a Senior Associate at Inkef from January 2019 to December 2021. There, they worked on the healthcare investment team. From June 2018 to August 2018, they were a Summer Associate at Forbion - Impacting the future of medicine, where they evaluated investment opportunities and supported ongoing fund's activities. Ivan also created a comprehensive market model for one of the portfolio companies and conducted research on management turnover and strategic change in pharmaceutical industry. Before that, they were with Skolkovo Foundation.

From January 2017 to January 2018, they were Business Development and Innovation manager at Sanofi. There, they were responsible for scouting and evaluation of post-POC opportunities to maximize top line growth of the regional affiliate and Global General Medicines & Emerging Markets business unit. Ivan was also responsible for scouting and evaluation of early-stage regional R&D start-ups and technologies in line with Sanofi's global strategy. Additionally, they supported in execution of out- , in-licensing, M&As and other alliances deals. Ivan was also the leader of the internal project aimed at fostering innovative culture within the affiliate. From July 2015 to December 2016, they served as Product planning manager Eurasia also at Sanofi.

Ivan Burkov has a Master of Business Administration from INSEAD, a Doctor of Philosophy in Genetics from the Institute of Cytology and Genetics, and is a Specialist in Cytology and Genetics from Novosibirsk State University. Ivan has also attended a summer school on technology transfer in life sciences at the Technische Universität Dresden, a life sciences commercialization pathfinder program at the CDRF Global foundation, and a summer school on innovations and technology commercialization at the Technopark of Novosibirsk.

Ivan Burkov reports to Roel Bulthuis, Managing Partner. Ivan Burkov works with Wolfgang Nöldeke - CFO, Laura Waldenstrӧm - Principal, and Frank Lansink - Operating Partner.